Sanctuary Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Sanctuary Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$216K	Sell	15,031 -3,459	-19%	-$38.5K	﹤0.01%	2577
2026 Q1	$172K	Sell	18,490 -15,971	-46%	-$144K	﹤0.01%	2400
2025 Q4	$309K	Buy	34,461 +5,247	+18%	+$49.6K	﹤0.01%	1993
2025 Q3	$278K	Buy	29,214 +1,264	+5%	+$12.7K	﹤0.01%	2047
2025 Q2	$246K	Buy	27,950 +19	+0.1%	+$154	﹤0.01%	2039
2025 Q1	$209K	Buy	27,931 +7	+0%	+$56	﹤0.01%	2014
2024 Q4	$224K	Hold	27,924	–	–	﹤0.01%	2184
2024 Q3	$268K	Sell	27,924 -77,000	-73%	-$523K	﹤0.01%	2066
2024 Q2	$474K	Buy	+104,924	New	+$497K	﹤0.01%	1677

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanctuary Advisors's ZVRA Position: Q2 2026 in Review

Sanctuary Advisors reduced its Zevra Therapeutics (ZVRA) stake by 19% in Q2 2026, selling an estimated $38.5K and leaving 15,031 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Sanctuary Advisors first reported a position in ZVRA in Q2 2024 and has held it in 9 quarters since. The position peaked at $474K in Q2 2024. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Sanctuary Advisors held 15,031 shares of Zevra Therapeutics worth $216K as of Q2 2026.
Sanctuary Advisors sold 3,459 Zevra Therapeutics shares in Q2 2026, an estimated $38.5K.
Zevra Therapeutics made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #2577 holding.
Sanctuary Advisors first reported a position in Zevra Therapeutics in Q2 2024 and has held it in 9 quarters since.
Sanctuary Advisors's Zevra Therapeutics position peaked at $474K in Q2 2024.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.